Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Zai Lab Ltd ADR
(NQ:
ZLAB
)
30.22
-0.62 (-2.01%)
Official Closing Price
Updated: 4:15 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
703,896
Open
30.63
Bid (Size)
30.22 (4)
Ask (Size)
30.24 (2)
Prev. Close
30.84
Today's Range
30.01 - 30.79
52wk Range
13.48 - 36.60
Shares Outstanding
956,637,360
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
October 29, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results
October 24, 2024
The company is working on an antibody drug conjugate, which is like a smart bomb for cancer cells.
Via
Investor's Business Daily
Performance
YTD
+15.96%
+15.96%
1 Month
+25.19%
+25.19%
3 Month
+58.80%
+58.80%
6 Month
+90.06%
+90.06%
1 Year
+19.92%
+19.92%
More News
Read More
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
October 24, 2024
Via
Benzinga
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
October 24, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in November and December Investor Conferences
October 18, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
October 17, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
October 16, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
October 09, 2024
From
Zai Lab Limited
Via
Business Wire
Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
September 25, 2024
Via
Benzinga
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
September 17, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
August 27, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in September Investor Conferences
August 22, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
August 06, 2024
From
Zai Lab Limited
Via
Business Wire
Why Is Zynex (ZYXI) Stock Down 24% Today?
July 26, 2024
Via
InvestorPlace
Topics
Earnings
Exposures
Financial
Why Is DexCom (DXCM) Stock Down 38% Today?
July 26, 2024
Via
InvestorPlace
Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem
July 26, 2024
Via
InvestorPlace
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
July 16, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
July 15, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
July 10, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
June 11, 2024
From
Zai Lab Limited
Via
Business Wire
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
June 04, 2024
Via
Benzinga
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
June 04, 2024
Via
Benzinga
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
May 22, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
May 20, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in May and June Investor Conferences
May 16, 2024
From
Zai Lab Limited
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.